C hen Qingzhou is a Chinese entrepreneur who is the chairman of Hybio Pharmaceutical, a company specializing in the research, development, and manufacturing of peptide-based drugs. Peptides are short chains of amino acids that are used in a variety of therapeutic applications, from treating diabetes to certain types of cancer. His fortune is derived from his family's controlling stake in the company.

Under his leadership, Hybio has become a leading domestic player in the specialized and high-tech field of peptide synthesis. The company produces both active pharmaceutical ingredients (APIs) and finished drug products. Chen's success is built on his company's scientific expertise and its ability to capitalize on the growing demand for advanced biopharmaceutical treatments within China's massive healthcare market. The company is publicly traded on the Shenzhen Stock Exchange.